A Life Sciences Research Institute in South America

The institute held promising preclinical data for a novel therapeutic diagnostic platform but required external strategic guidance to structure a commercially viable spinout company and attract international venture capital. The institution faced increasing pressure to bridge academic discovery with commercial adoption, requiring structured governance, clear IP policies, and multi-disciplinary collaboration frameworks to overcome traditional research silos.

Oxford Oracle provided comprehensive venture building services, including business model formulation, IP valuation, regulatory strategy mapping, and investor pitch preparation for the founding scientific team. Oxford Oracle deployed a multidisciplinary advisory team to execute comprehensive technical due diligence, design bespoke commercialisation roadmaps, and establish standardized stage-gate evaluation metrics.

The resulting life sciences spinout closed a £4.5 million Series A investment round led by international healthcare venture funds, enabling the platform to advance into Phase II clinical trials. Furthermore, the engagement established a permanent, scalable operational blueprint, driving long-term strategic alignment, continuous revenue growth, and enhanced institutional reputation across global innovation networks.